VeraDermics
MANE
VeraDermics (MANE) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Citigroup | Maintained | Buy | $160.00 from $135.00 | Jul 16, 2026 |
| B. Riley Securities | Initiated Coverage | Buy | $170.00 | Jul 15, 2026 |
| Needham | Maintained | Buy | $164.00 from $136.00 | Jul 15, 2026 |
| Jefferies | Maintained | Buy | $182.00 from $138.00 | Jul 7, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $135.00 | Jun 16, 2026 |
| Needham | Initiated Coverage | Buy | $136.00 | Jun 2, 2026 |
| Citigroup | Maintained | Buy | $135.00 from $120.00 | May 18, 2026 |
| Leerink Partners | Maintained | Outperform | $90.00 from $75.00 | Apr 22, 2026 |
| Jefferies | Initiated Coverage | Buy | $75.00 | Mar 2, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $75.00 | Mar 2, 2026 |
| Citigroup | Initiated Coverage | Buy | $85.00 | Mar 2, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Mar 2, 2026 |
Frequently asked questions
What is the latest analyst rating on MANE?
On Jul 16, 2026, Citigroup maintained VeraDermics at Buy with a price target of $160.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.